AgeX Therapeutics, Inc. (AGE) Financial Statements (2023 and earlier)

Company Profile

Business Address 1101 MARINA VILLAGE PARKWAY
ALAMEDA, CA 94501
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6455845272,3526,707
Cash and cash equivalents6455845272,3526,707
Restricted cash and investments695634   
Receivables425326363131
Other undisclosed current assets1,1099911,4301,3391,015
Total current assets:2,4532,2342,2834,0547,853
Noncurrent Assets
Property, plant and equipment    1,12690
Long-term investments and receivables     
Accounts and financing receivable, after allowance for credit loss     
Intangible assets, net (including goodwill)7388701,5922,1512,709
Intangible assets, net (excluding goodwill)7388701,5922,1512,709
Deposits noncurrent assets  505011119
Restricted cash and investments50    
Total noncurrent assets:7889201,6423,3882,818
TOTAL ASSETS:3,2413,1543,9257,44210,671
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,0347711,6561,5821,416
Employee-related liabilities212228263254
Accounts payable568193761420150
Accrued liabilities273    
Other undisclosed accounts payable and accrued liabilities1933666678991,012
Deferred revenue   275283
Debt7,646 436428 
Due to related parties 1417,1401,9606482
Contract with customer, liability317
Other liabilities     625
Other undisclosed current liabilities1,2571,0561,030940 
Total current liabilities:10,0788,9675,3573,2972,440
Noncurrent Liabilities
Long-term debt and lease obligation10,478    
Long-term debt, excluding current maturities10,478    
Liabilities, other than long-term debt  6,0623,9641,528 
Deferred revenue   64 
Due to related parties  6,0623,9001,528 
Total noncurrent liabilities:10,4786,0623,9641,528 
Total liabilities:20,55615,0299,3214,8252,440
Equity
Equity, attributable to parent, including:(17,212)(11,832)(5,116)2,2187,447
Common stock44444
Common stock held by subsidiary (3,248)   
Additional paid in capital98,99493,91291,81088,35381,499
Accumulated other comprehensive income (loss)   14369(2)
Accumulated deficit(116,210)(105,748)(97,073)(86,208)(74,054)
Other undisclosed equity, attributable to parent 3,248   
Equity, attributable to noncontrolling interest(103)(43)(280)399784
Total equity:(17,315)(11,875)(5,396)2,6178,231
TOTAL LIABILITIES AND EQUITY:3,2413,1543,9257,44210,671

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues341441,8681,7281,396
Cost of revenue(13)(19)(158)(244)(364)
Gross profit:211251,7101,4841,032
Operating expenses(6,996)(8,164)   
Other undisclosed operating income (loss)  106  (12,277)
Operating income (loss):(6,975)(7,933)1,7101,484(11,245)
Nonoperating expense(3,547)(649)   
Other nonoperating income13448   
Interest and debt expense(3,335)437(487)(54) 
Other undisclosed loss from continuing operations before equity method investments, income taxes   (12,349)(13,666) 
Loss from continuing operations before equity method investments, income taxes:(13,857)(8,145)(11,126)(12,236)(11,245)
Other undisclosed income (loss) from continuing operations before income taxes24,357(540)   
Income (loss) from continuing operations before income taxes:10,500(8,685)(11,126)(12,236)(11,245)
Other undisclosed income (loss) from continuing operations(21,022)8,688   
Income (loss) from continuing operations:(10,522)3(11,126)(12,236)(11,245)
Income (loss) before gain (loss) on sale of properties:(100)(11,126)(12,236)(11,245)
Loss from discontinued operations  (103)   
Other undisclosed net income (loss) (8,585)   
Net loss:(10,522)(8,685)(11,126)(12,236)(11,245)
Net income attributable to noncontrolling interest60 111230229
Other undisclosed net income (loss) attributable to parent 10150(148)3,514
Net loss attributable to parent:(10,462)(8,675)(10,865)(12,154)(7,502)
Other undisclosed net income (loss) available to common stockholders, basic 17,254   
Net income (loss) available to common stockholders, diluted:(10,462)8,579(10,865)(12,154)(7,502)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(10,522)(8,685)(11,126)(12,236)(11,245)
Other comprehensive loss(10,462)(8,818)(10,791)(12,083)(7,572)
Other undisclosed comprehensive income     
Comprehensive loss:(20,984)(17,503)(21,917)(24,319)(18,817)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest60 111230(229)
Other undisclosed comprehensive income, net of tax, attributable to parent10,4028,67510,90411,77626,847
Comprehensive income (loss), net of tax, attributable to parent:(10,522)(8,828)(10,902)(12,313)7,801

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: